色氨酸代谢
免疫系统
卵巢癌
卵巢癌
分解代谢
吲哚胺2,3-双加氧酶
癌症
医学
机制(生物学)
癌症研究
免疫学
肿瘤科
生物
内科学
色氨酸
新陈代谢
哲学
氨基酸
认识论
生物化学
作者
Lynelle P Smith,Benjamin G. Bitler,Jennifer K. Richer,Jessica L. Christenson
出处
期刊:PubMed
日期:2019-01-01
卷期号:14: 1-9
被引量:5
摘要
Ovarian cancers are the most common cause of gynecological death, and the five-year survival rate for women diagnosed with epithelial ovarian carcinoma (EOC) remains extremely low at only 47%. Recent studies have highlighted the importance of the anti-tumor immune response in determining EOC clinical outcomes, and much research is currently being undertaken in an effort to reverse tumor immune evasion. One mechanism known to promote tumor immune evasion in multiple cancer types is tryptophan catabolism. Here we review the potential role of two rate-limiting enzymes that evolved separately to catabolize tryptophan, indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase 2 (TDO2), that may be active in ovarian cancers and result in the production of immune suppressive catabolites. Research to date has focused on IDO inhibitors, currently in clinical trials, but these therapies fail to inhibit TDO2. However, our mining of publically available data from clinical specimens suggest that TDO2 may also need to be targeted in ovarian cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI